Male breast cancer - How to treat?

Breast Cancer Online

Volumn 10, Issue 8, 2007, Pages

  Rossmann, Eva D ^a,b   Liljegren, A ^a,b   Bergh, J ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer; Male; Treatment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADRENALECTOMY; AGE; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CRYPTORCHISM; DEPRESSION; DISEASE FREE SURVIVAL; FAMILY HISTORY; HOT FLUSH; HUMAN; HYPOPHYSECTOMY; IMPOTENCE; KLINEFELTER SYNDROME; LIBIDO DISORDER; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MALE; MALE BREAST; MASTECTOMY; MULTIMODALITY CANCER THERAPY; OBESITY; ORCHIECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; WEIGHT GAIN;

EID: 35048848396     PISSN: 14709031     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1470903107006463     Document Type: Article

References (53)

1. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367: 595-604.
2. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137: 678-687.
3. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: A population-based study. Cancer 2004; 101 51-57.
4. Malani AK. Male breast cancer: A different disease than female breast cancer? South Med J 2007; 100: 197.
5. Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the veterans affairs population: A comparative analysis. Cancer 2007; 109: 1471-1477.
6. Czene K, Bergqvist J, Hall P, Bergh J. How to treat male breast cancer. The Breast; 2007.
7. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: A review of clinical management. Breast Cancer Res Treat 2007; 103: 11-21.
8. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83: 77-86.
9. Goss PE, Reid C, Pintille M, Lim R, Miller N. Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85: 629-639.
10. Crew KD, Neugut AI, Wang X, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007; 25: 1089-1098.
11. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10: 471-479.
12. Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57: 1-7.
13. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007; 8: 193-202.
14. Culell P, Solernou L, Tarazona J, et al. Male breast cancer: A multicentric study. Breast J 2007; 13: 213-215.
15. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106.
16. Gennari R, Curigliano G, Jereczek-Fossa BA, et al. Male breast cancer: A special therapeutic problem. Anything new? (Review). Int J Oncol 2004; 24: 663-670.
17. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
18. Bergh J, Jonsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40: 253-281.
19. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
20. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: Medical perspectives. Clin Cancer Res 2001; 7: 4388s-4391s, discussion 4411s-4412s.
21. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
22. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
23. Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995; 31A: 1960-1964.
24. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: A multiinstitutional survey. Cancer 1998; 83: 498-509.
25. Stierer M, Rosen H, Weitensfelder W, et al. Male breast cancer: Austrian experience. World J Surg 1995; 19: 687-692, discussion 683-692.
26. Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: An analysis of 170 cases. Eur J Cancer 1994; 30A: 930-935.
27. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992; 65: 252-254.
28. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989; 64: 1583-1585.
29. Yildirim E, Berberoglu U. Male breast cancer: A 22-year experience. Eur J Surg Oncol 1998; 24: 548-552.
30. Ribeiro G. Male breast carcinoma - a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 1985; 51: 115-119.
31. Donegan WL, Redlich PN. Breast cancer in men. Surg Clin North Am 1996; 76: 343-363.
32. Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74: 74-77.
33. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
34. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
35. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369: 559-570.
36. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000; 85: 2370-2377.
37. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006; 24: E42-43.
38. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987; 10: 55-60.
39. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005; 104: 2359-2364.
40. Walshe JM, Berman AW, Vatas U, et al. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 2007; 103: 177-183.
41. Ravandi-Kashani F, Hayes TG. Male breast cancer: A review of the literature. Eur J Cancer 1998; 34: 1341-1347.
42. Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84: 215-223.
43. Wang-Rodriguez J, Cross K, Gallagher S, et al. Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15: 853-861.
44. Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer 1998; 83: 1947-1955.
45. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in Her-2/ neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436.
46. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
47. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
49. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992; 117: 771-777.
50. Franco A, Chlebowski F. Discordance in estrogen (ER) and progesteron (PR) status between primary metastatic breast cancer: A meta-analysis. In: Perry M (ed.). 40th Annual Meeting of the ASCO, New Orleans, LA, 2004.
51. Gancberg D, Di Lec A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-1043.
52. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002; 25: 235-237.
53. Italiano A, Largillier R, Marcy PY, et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 2004; 25: 323-324.